Adam Burgess, Olivia Allen, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Robert Bowser, Javier Mascias Cadavid, Gregory T Carter, Merit Cudkowicz, Keelie Denson, Kara Dyckman, Basil Elsharif, Eva Feldman, Juliette Foucher, Timothy Fullum, Jonathan Glass, Benjamin Helmold, Carlayne Jackson, Sartaj Jhooty, Ariah Leday, Elise Mallon, Christopher Mcdermott, Natasha Olby, Lyle Ostrow, Gary Pattee, Erik Pioro, Dylan Ratner, Hemangi Sang, Elia Tito, Fernando Vieira, Paul Wicks, Richard Bedlack, Dario Gelevski
{"title":"ALS untangled #83: clenbuterol.","authors":"Adam Burgess, Olivia Allen, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Robert Bowser, Javier Mascias Cadavid, Gregory T Carter, Merit Cudkowicz, Keelie Denson, Kara Dyckman, Basil Elsharif, Eva Feldman, Juliette Foucher, Timothy Fullum, Jonathan Glass, Benjamin Helmold, Carlayne Jackson, Sartaj Jhooty, Ariah Leday, Elise Mallon, Christopher Mcdermott, Natasha Olby, Lyle Ostrow, Gary Pattee, Erik Pioro, Dylan Ratner, Hemangi Sang, Elia Tito, Fernando Vieira, Paul Wicks, Richard Bedlack, Dario Gelevski","doi":"10.1080/21678421.2026.2638588","DOIUrl":null,"url":null,"abstract":"<p><p>ALS Untangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review clenbuterol, a β-2 adrenergic agonist, as a potential treatment for amyotrophic lateral sclerosis (ALS). Clenbuterol has biological effects that could be relevant to the pathophysiology of ALS such as inducing muscle hypertrophy, improving mitochondrial function, and reducing neuroinflammation. Two studies in mouse models of motor neuron disease and two open label trials suggest possible benefits. However these have methodological flaws which limit interpretation. Clenbuterol can have an array of side effects, some severe. Drop-outs due to side effects were very common in one of the ALS trials and in a separate expanded access program. Based on this information, we cannot currently endorse clenbuterol as an ALS treatment, but we do hope to see further studies of it, or another long acting β-2 adrenergic agonist in people with ALS.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"949-956"},"PeriodicalIF":2.8000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2026.2638588","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ALS Untangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review clenbuterol, a β-2 adrenergic agonist, as a potential treatment for amyotrophic lateral sclerosis (ALS). Clenbuterol has biological effects that could be relevant to the pathophysiology of ALS such as inducing muscle hypertrophy, improving mitochondrial function, and reducing neuroinflammation. Two studies in mouse models of motor neuron disease and two open label trials suggest possible benefits. However these have methodological flaws which limit interpretation. Clenbuterol can have an array of side effects, some severe. Drop-outs due to side effects were very common in one of the ALS trials and in a separate expanded access program. Based on this information, we cannot currently endorse clenbuterol as an ALS treatment, but we do hope to see further studies of it, or another long acting β-2 adrenergic agonist in people with ALS.
ALS Untangled回顾了肌萎缩性侧索硬化症（PALS）患者的替代治疗和标签外治疗。本文回顾了盐酸克仑特罗，一种β-2肾上腺素能激动剂，作为肌萎缩性侧索硬化症（ALS）的潜在治疗方法。盐酸克仑特罗具有诱导肌肉肥大、改善线粒体功能、减轻神经炎症等生物学效应，可能与ALS的病理生理有关。两项运动神经元疾病小鼠模型研究和两项开放标签试验表明可能有益。然而，这些方法上的缺陷限制了解释。盐酸克仑特罗有一系列副作用，有些还很严重。在一项ALS试验和另一项扩大准入计划中，由于副作用而退出的情况非常普遍。基于这些信息，我们目前不能支持克伦特罗作为渐冻人症的治疗方法，但我们确实希望看到它的进一步研究，或者另一种长效β-2肾上腺素能激动剂用于渐冻人症患者。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
